Trends in Kaposi’s Sarcoma in Miami Beach from 1987 to 2007

Purpose. Kaposi’s sarcoma (KS) is a rare low-grade vascular tumor associated with the human herpes virus 8. By analyzing the epidemiology, staging, and treatment of KS, we hoped to improve the quality of care at our institution. Methods. Review of the Mount Sinai Medical Center tumor registry database in Miami Beach, FL, USA, identified 143 cases of KS between January 1, 1987 and December 31, 2007. Results. The majority of patients were non-Hispanic whites, non smoking males diagnosed between 1987 and 1996. Most of the patients were HIV positive, with an equal percentage diagnosed with local or distant disease. Most patients received no chemotherapy or radiation. There were no significant differences in patient survival based on sex, HIV status, or radiation received. There was a trend toward improved survival among older patients who smoked, received no chemotherapy, and had localized stage at diagnosis. Multivariate analysis revealed that non-Hispanic whites had a significant worse survival than Hispanic whites (HR = 0.55, 95% CI (0.33, 0.90), ). Patients diagnosed between 1987 and 1996 had a worse survival than those between 1997 and 2007 (HR = 0.33 (95% CI 0.19, 0.55), ). Conclusion. This large retrospective study provides further insight into KS. Ethnicity and date of diagnosis are important predictors of long-term survival.

Download Full-text

Long Term Survival of Male Homosexual Patients with Kaposi's Sarcoma

Journal of the Royal Society of Medicine ◽

10.1177/014107688908200416 ◽

1989 ◽

Vol 82 (4) ◽

pp. 226-227 ◽

Cited By ~ 8

Author(s):

C P Lowdell ◽

M G Glaser

Keyword(s):

Kaposi's Sarcoma ◽

Kaposi’S Sarcoma ◽

Term Survival ◽

Long Term Survival ◽

Male Homosexual

Download Full-text

Management of an oncological wound: Diagnosis, conflicting therapies and decision-making

10.35279/jewma202011.03 ◽

2020 ◽

Vol 21 (Issue 1 Volume 21, 2020) ◽

pp. 13-16

Author(s):

Tommaso Bianchi ◽

Ambra Di Altobrando ◽

Yuri Merli ◽

Federico Tartari ◽

Barbara Manfredi ◽

...

Keyword(s):

Bullous Pemphigoid ◽

Kaposi's Sarcoma ◽

Kaposi’S Sarcoma ◽

Hiv Positive ◽

Low Grade ◽

Vascular Tumour ◽

Human Herpes ◽

Human Herpes Virus 8 ◽

Human Herpes Virus ◽

Blistering Disease

This article presents the case of a non-HIV-positive patient who contemporaneously suffered from Kaposi’s sarcoma and bullous pemphigoid. Kaposi’s sarcoma is a rare low-grade vascular tumour associated with human herpes virus 8 infection, while bullous pemphigoid is the most common autoimmune subepidermal blistering disease in western countries.

Download Full-text

Anogenital Lesions: Kaposi's Sarcoma and Its Mimicks

ISRN AIDS ◽

10.5402/2012/486425 ◽

2012 ◽

Vol 2012 ◽

pp. 1-5 ◽

Cited By ~ 1

Author(s):

Louis-Jacques van Bogaert

Keyword(s):

Kaposi's Sarcoma ◽

Kaposi’S Sarcoma ◽

Final Diagnosis ◽

Hiv Positive ◽

Low Grade ◽

Vascular Neoplasm ◽

Human Herpes Virus 8 ◽

Sexually Transmitted ◽

Immunodeficiency Virus ◽

Hiv Serostatus

Kaposi's sarcoma (KS) is a low-grade vascular neoplasm associated with human herpes virus-8 (HHV-8) infection, and, in the epidemic form, with the human immunodeficiency virus (HIV). Although HHV-8 is present in all body fluids and is sexually transmitted, there are surprisingly few reports of anogenital KS. Clinically, especially in HIV/KS endemic areas, dark stained skin patches or nodules are prone to misdiagnosis, especially in dark-skinned individuals. Therefore, a biopsy is recommended. The histologic appearance spans a broad spectrum of KS and non-KS lesions; therefore, the final diagnosis should be confirmed by HHV-8 immunohistochemistry. We report a series of 36 anogenital biopsies from a group of 16 documented HIV-positive patients; in 20 the HIV serostatus was unknown. There were ten KS (five in HIV-positive patients), and 26 non-KS (11 in HIV-positive subjects) lesions. In the era of HIV/AIDS, anogenital lesions may be the first manifestation of KS in immunocompromised individuals and should be biopsied. The histological diagnosis should be confirmed by HHV-8 immunohistochemistry.

Download Full-text

MOLECULAR DETECTION OF KAPOSI’S SARCOMA ASSOCIATED VIRUS (HUMAN HERPES VIRUS 8) IN SINO-NASAL CARCINOMA TISSUES

10.36295/asro.2020.23434 ◽

2020 ◽

Vol 23 (04) ◽

pp. 286-297

Author(s):

Hind Hamed Shaker ◽

Luma Amer Yasir ◽

Ausama Abed-Alkadum Alajeely ◽

Saad Hasan Mohammed Ali ◽

Shakir H. Mohammed Al-Alwany

Keyword(s):

Kaposi's Sarcoma ◽

Herpes Virus ◽

Molecular Detection ◽

Kaposi’S Sarcoma ◽

Human Herpes ◽

Human Herpes Virus 8 ◽

Human Herpes Virus ◽

Herpès Virus ◽

Nasal Carcinoma

Download Full-text

Influence of Postoperative Changes in Sarcopenia on Long-Term Survival in Non-Metastatic Colorectal Cancer Patients

Cancers ◽

10.3390/cancers13102410 ◽

2021 ◽

Vol 13 (10) ◽

pp. 2410

Author(s):

Chungyeop Lee ◽

In-Ja Park ◽

Kyung-Won Kim ◽

Yongbin Shin ◽

Seok-Byung Lim ◽

...

Keyword(s):

Colorectal Cancer ◽

Metastatic Colorectal Cancer ◽

Cancer Patients ◽

Medical Center ◽

The Body ◽

Term Survival ◽

Postoperative Changes ◽

Asan Medical ◽

Colorectal Cancer Patients

The effect of perioperative sarcopenic changes on prognosis remains unclear. We conducted a retrospective cohort study with 2333 non-metastatic colorectal cancer patients treated between January 2009 and December 2012 at the Asan Medical Center. The body composition at diagnosis was measured via abdominopelvic computed tomography (CT) using Asan-J software. Patients underwent CT scans preoperatively, as well as at 6 months–1 year and 2–3 years postoperatively. The primary outcome was the association between perioperative sarcopenic changes and survival. According to sarcopenic criteria, 1155 (49.5%), 890 (38.2%), and 893 (38.3%) patients had sarcopenia preoperatively, 6 months–1 year, and 2–3 years postoperatively, respectively. The 5-year overall survival (OS) (95.8% vs. 92.1%, hazard ratio (HR) = 2.234, p < 0.001) and 5-year recurrence-free survival (RFS) (93.2% vs. 86.2%, HR = 2.251, p < 0.001) rates were significantly lower in patients with preoperative sarcopenia. Both OS and RFS were lower in patients with persistent sarcopenia 2–3 years postoperatively than in those who recovered (OS: 96.2% vs. 90.2%, p = 0.001; RFS: 91.1% vs. 83.9%, p = 0.002). In multivariate analysis, postoperative sarcopenia was confirmed as an independent factor associated with decreased OS and RFS. Pre- and postoperative sarcopenia and changes in the condition during surveillance were associated with oncological outcomes.

Download Full-text

Long-Term Tacrolimus Blood Trough Level and Patient Survival in Adult Liver Transplantation

Journal of Personalized Medicine ◽

10.3390/jpm11020090 ◽

2021 ◽

Vol 11 (2) ◽

pp. 90

Author(s):

Chih-Yang Hsiao ◽

Ming-Chih Ho ◽

Cheng-Maw Ho ◽

Yao-Ming Wu ◽

Po-Huang Lee ◽

...

Keyword(s):

Patient Survival ◽

Trough Level ◽

Medical Center ◽

Term Survival ◽

Blood Concentrations ◽

Long Term Survival ◽

Tacrolimus Level ◽

Cox's Model ◽

The Impact

Tacrolimus is the most widely used immunosuppressant in liver transplant (LT) patients. However, the ideal long-term target level for these patients is unknown. This retrospective study aimed to investigate the impact of tacrolimus blood concentration five years after LT on long-term patient survival outcomes in adult LT recipients. Patients who underwent LT between January 2004 and July 2014 at a tertiary medical center were included in this study (n = 189). The mean tacrolimus blood concentrations of each patient during the fifth year after LT were recorded and the overall survival rate was determined. A multivariate analysis of factors associated with long-term survival was conducted using a Cox’s model. The median follow-up period was 9.63 years, and 144 patients (76.2%) underwent live donor LT. Sixteen patients died within 5 years of LT. In the Cox’s model, patients with a mean tacrolimus blood trough level of 4.6–10.2 ng/mL had significantly better long-term survival than those with a mean tacrolimus blood trough level outside this range (estimated hazard ratio = 4.76; 95% confidence interval: 1.34–16.9, p = 0.016). Therefore, a tacrolimus level no lower than 4.6 ng/mL would be recommended in adult LT patients.

Download Full-text

Fertility preservation in women with early ovarian cancer

Hormone Molecular Biology and Clinical Investigation ◽

10.1515/hmbci-2020-0026 ◽

2020 ◽

Vol 0 (0) ◽

Author(s):

Daniel Necula ◽

Daria Istrate ◽

Jérôme Mathis

Keyword(s):

Ovarian Cancer ◽

Fertility Preservation ◽

Low Grade ◽

Term Survival ◽

Organizational Issues ◽

Fertility Sparing Surgery ◽

Fertility Sparing ◽

Early Ovarian Cancer ◽

Reproductive Techniques

AbstractFertility preservation is an important option to consider for young women with low-grade early ovarian cancer. Fertility-sparing surgery (“FSS”) permits the conservation of the uterus and one of the ovaries. This technique is considered safe for stages IA G1, G2 and probably safe for IC G1 epithelial and non-epithelial ovarian cancers. There are still uncertainties and FSS is not fully accepted for stage IC G1, G2 and clear cell carcinoma. The difficulty in choosing the best option lies in the fact that there is a lack of prospective randomized studies, due to ethical and organizational issues. Retrospective studies and reviews showed reassuring results for FSS in terms of relapse and long term survival. The spontaneous pregnancy rate seems to decrease after FSS, but chemotherapy does not seem to have an impact on fertility rates. Compared with the general population, assisted reproductive techniques are considered safe and with similar fertility results.

Download Full-text

687. Iatrogenic Kaposi’s Sarcoma Following Treatment with Vedolizumab

Open Forum Infectious Diseases ◽

10.1093/ofid/ofaa439.879 ◽

2020 ◽

Vol 7 (Supplement_1) ◽

pp. S397-S397

Author(s):

Susanne O Ajao ◽

Hamid Shaaban ◽

Rajasingam Jayasingam

Keyword(s):

Blood Cell ◽

Cell Count ◽

Kaposi's Sarcoma ◽

Symptomatic Relief ◽

Kaposi’S Sarcoma ◽

Immunosuppressive Drugs ◽

Lymph Node Biopsy ◽

Human Herpes Virus 8 ◽

Spindle Cells ◽

Spindle Cell Proliferation

Abstract Background Kaposi’s sarcoma (KS) is a vascular tumor caused by human herpes virus-8 infection (HHV-8) commonly involving the skin. We report a case of a patient with controlled HIV who developed Kaposi’s sarcoma on vedolizumab. Darkened hyperkeratotic plaque on his left medial foot Methods A 39-year-old homosexual male with a history of Ulcerative Colitis (UC), Hodgkin’s lymphoma in remission and HIV presented with complaints of abdominal pain and bloody diarrhea. He had new tender lesions on his left foot which was absent at his previous admission a month ago. The lesions started as macules and later progressed to tender lesions. Mesalamine and oral corticosteroids were previously prescribed without symptomatic relief and he was started on vedolizumab 2 months ago. On physical exam he had abdominal tenderness, tender cervical and inguinal lymph nodes, and dark macules on his feet. Digital rectal exam revealed bloody mucoid stool. Laboratory showed white blood cell count of 12,600/mm3, ESR of 132 mm/hr and CRP of 4.6 mg/dL. His CD4 T-cell count was 873 cells/mm3 and viral load was 50 copies per milliliter. Cervical lymph node biopsy showed polymorphous population of lymphocytes but was negative for malignant cells. Biopsy of the foot plaques showed atypical intradermal vascular and spindle cell proliferation positive for HHV-8 and for vascular marker CD34. The results were consistent with the diagnosis of KS. Serology was also positive for HHV-8 with high viral titers of 74 copies/mL. Colonoscopy showed severe proctitis with deep ulcerations in a continuous pattern in the rectum with a normal sigmoid colon. Follow up colonoscopy showed improved proctitis and he was started on doxorubicin to treat KS with improvement of the foot lesion a month later following treatment. Dark macules on the sole of both feet Figure 3a: Spindle cells with irregular small vessel proliferation and red blood cell extravasation between tumor cells Figure 3b: Immunohistochemical stain showing HHV-8 expression of spindle cells Improvement of the foot lesion Results Vedolizumab is a monoclonal antibody that prevents the recruitment of lymphocytes to the inflamed tissue. It is approved for the treatment of IBD and has shown efficacy and safety. The iatrogenic form of Kaposi’s sarcoma occurs in patients on immunosuppressive therapy, as this patient. Conclusion Patients with IBD on immunosuppressive drugs should be followed up closely and screened for latent viral infections prior to initiating therapy. As in the patient, HHV-8 should be recognized as a likely underlying opportunistic infection in immunocompromised patients with IBD. Disclosures All Authors: No reported disclosures

Download Full-text